Art. 10 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 28 Jan 2022cited 54×
1.

Within 15 days after receipt of the opinion referred to in Article 5(2), the Commission shall prepare a draft of the decision to be taken in respect of the application.

Where a draft decision envisages the granting of a marketing authorisation, it shall include or make reference to the documents mentioned in points (a) to (d) of Article 9(4).

Where a draft decision envisages the granting of a marketing authorisation subject to the conditions referred to in points (c), (ca), (cb), or (cc) of Article 9(4), it shall lay down deadlines for the fulfilment of the conditions, where necessary.

Where the draft decision differs from the opinion of the Agency, the Commission shall attach a detailed explanation of the reasons for the differences.

The draft decision shall be forwarded to Member States and the applicant.

2.

The Commission shall, by means of implementing acts, take a final decision within 15 days after obtaining the opinion of the Standing Committee on Medicinal Products for Human Use. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 87(2).

3.

The Standing Committee on Medicinal Products for Human Use referred to in Article 87(1) shall adjust its rules of procedure so as to take account of the tasks incumbent upon it under this Regulation.

The adjustments shall provide that:

(a)

the opinion of the said Standing Committee is to be given in writing;

(b)

Member States shall have 22 days to forward their written observations on the draft decision to the Commission. However, if a decision has to be taken urgently, a shorter time-limit may be set by the Chairman according to the degree of urgency involved. This time-limit shall not, otherwise than in exceptional circumstances, be shorter than 5 days;

(c)

Member States may request in writing that the draft decision referred to in paragraph 1 be discussed by a plenary meeting of the said Standing Committee, stating their reasons in detail.

4.

Where, in the opinion of the Commission, a Member State's written observations raise important new questions of a scientific or technical nature which the opinion delivered by the Agency has not addressed, the Chairman shall suspend the procedure and refer the application back to the Agency for further consideration.

5.

The Commission shall, by means of implementing acts, adopt detailed rules for the implementation of paragraph 4 which specify the applicable time limits and procedures. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 87(2).

6.

The Agency shall disseminate the documents referred to in points (a) to (d) of Article 9(4), together with any deadlines laid down pursuant to the third subparagraph of paragraph 1 of this Article.

The 10 that are cited most themselves, of 54.

  • Directive (EU) 2001/83107g107k5aLaw

    … в първа алинея, буква б) от настоящия параграф, се прилага член 10 от Регламент (ЕО) № 726/2004. Когато Комисията приеме такова решение, …

  • Judgment of the General Court (Seventh Chamber, Extended Composition) of 5 May 2021. Pharmaceutical Works Polpharma S.A. v European MedicineDecision

    On 10 January 2014, one of the members of the Standing Committee on Medicinal Products for Human Use requested that a plenary meeting of that committee be held in accordance with Article 10(3)(c) of Regulation No 726/2004. That member …

    5 May 2021 · 62018TJ0611

  • Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 Decembe…Lawamends

  • Commission Regulation (EC) No 507/2006 of 29 March 2006 on the conditional marketing aut…6Law

    … на решение от Комисията в съответствие с разпоредбите на член 10 от Регламент (ЕО) № 726/2004.

  • Directive (EU) 2010/841Law

    … в първа алинея, буква б) от настоящия параграф, се прилага член 10 от Регламент (ЕО) № 726/2004. Когато Комисията приеме такова решение, …

  • Regulation (EU) 2019/5Lawamends

  • Judgment of the General Court (Sixth Chamber) of 19 December 2019. Vanda Pharmaceuticals Ltd v European Commission.Decision

    These considerations apply mutatis mutandis to the CHMP assessment report, which itself forms part of the CHMP opinion. Neither an opinion nor an assessment report of the CHMP can be regarded as a definitive measure, since their only …

    19 Dec 2019 · 62018TJ0211

  • The Human Medicines Regulations 201231Law

    … decision has been made by the European Commission in relation to the grant of an EU marketing authorisation under Article 10 of Regulation (EC) No 726/2004. (2) Where this sub-paragraph applies, the applicant may apply to the licensing …

  • The Human Medicines (Amendment etc.) (EU Exit) Regulations 201971Law

    … has been made by the European Commission in relation to the grant of an European Union marketing authorisation under Article 10 of Regulation (EC) No 726/2004. (2) Where this paragraph applies and the applicant for the European Union …

  • Commission Regulation (EC) No 658/2007 of 14 June 2007 concerning financial penalties fo…1Law

    … продукт, както е посочено в член 9, параграф 4, буква б), член 10, параграф 1, втора алинея, член 34, параграф 4, буква в) и член 35, параграф 1, …